A novel combined chemotherapy using TS-1 and low-dose cisplatin against liver metastasis of gastric cancer

Yoshiro Saikawa, Toshio Kanai, Yukio Kawano, Yoshihide Otani, Tetsuro Kubota, Masaki Kitajima

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We used a novel combination chemotherapy of TS-1 and low-dose cisplatin (CDDP) with 4 gastric cancer patients with liver metastases (one far advanced and 3 recurrent patients). TS-1 was administered at 80 mg-120 mg/body/day, twice daily for 3 weeks followed by a 2-week interval as one cycle, and CDDP was administered at 6 mg/m2/day div, for 5 days followed by a 2-day interval (1 cycle for an inpatient) or at 6 mg/m2/day div, at 5 times for 2-3 weeks (1 cycle for an outpatient). Efficacy and toxicity were evaluated after 3-6 cycles of the regimen, as long as the patients tolerated the regimen without severe side effects. This regimen resulted in 1 complete response, 2 partial responses and 1 progressive disease, showing a 75% efficacy rate. One patient experienced grade 2 nausea from this regimen, which was ameliorated by means of prolonging the interval of CDDP-administration. Thus, the regimen is useful to maintain patients' quality of life without severe adverse effects, and has a high efficacy in gastric cancer patients with liver metastases.

Original languageEnglish
Pages (from-to)1241-1245
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume29
Issue number7
Publication statusPublished - 2002 Jul

Fingerprint

Cisplatin
Stomach Neoplasms
Neoplasm Metastasis
Drug Therapy
Liver
Combination Drug Therapy
Nausea
titanium silicide
Inpatients
Outpatients
Quality of Life

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Saikawa, Y., Kanai, T., Kawano, Y., Otani, Y., Kubota, T., & Kitajima, M. (2002). A novel combined chemotherapy using TS-1 and low-dose cisplatin against liver metastasis of gastric cancer. Japanese Journal of Cancer and Chemotherapy, 29(7), 1241-1245.

A novel combined chemotherapy using TS-1 and low-dose cisplatin against liver metastasis of gastric cancer. / Saikawa, Yoshiro; Kanai, Toshio; Kawano, Yukio; Otani, Yoshihide; Kubota, Tetsuro; Kitajima, Masaki.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 29, No. 7, 07.2002, p. 1241-1245.

Research output: Contribution to journalArticle

Saikawa, Y, Kanai, T, Kawano, Y, Otani, Y, Kubota, T & Kitajima, M 2002, 'A novel combined chemotherapy using TS-1 and low-dose cisplatin against liver metastasis of gastric cancer', Japanese Journal of Cancer and Chemotherapy, vol. 29, no. 7, pp. 1241-1245.
Saikawa, Yoshiro ; Kanai, Toshio ; Kawano, Yukio ; Otani, Yoshihide ; Kubota, Tetsuro ; Kitajima, Masaki. / A novel combined chemotherapy using TS-1 and low-dose cisplatin against liver metastasis of gastric cancer. In: Japanese Journal of Cancer and Chemotherapy. 2002 ; Vol. 29, No. 7. pp. 1241-1245.
@article{6ea1cbea4fcd451fb59a921b6df3e303,
title = "A novel combined chemotherapy using TS-1 and low-dose cisplatin against liver metastasis of gastric cancer",
abstract = "We used a novel combination chemotherapy of TS-1 and low-dose cisplatin (CDDP) with 4 gastric cancer patients with liver metastases (one far advanced and 3 recurrent patients). TS-1 was administered at 80 mg-120 mg/body/day, twice daily for 3 weeks followed by a 2-week interval as one cycle, and CDDP was administered at 6 mg/m2/day div, for 5 days followed by a 2-day interval (1 cycle for an inpatient) or at 6 mg/m2/day div, at 5 times for 2-3 weeks (1 cycle for an outpatient). Efficacy and toxicity were evaluated after 3-6 cycles of the regimen, as long as the patients tolerated the regimen without severe side effects. This regimen resulted in 1 complete response, 2 partial responses and 1 progressive disease, showing a 75{\%} efficacy rate. One patient experienced grade 2 nausea from this regimen, which was ameliorated by means of prolonging the interval of CDDP-administration. Thus, the regimen is useful to maintain patients' quality of life without severe adverse effects, and has a high efficacy in gastric cancer patients with liver metastases.",
author = "Yoshiro Saikawa and Toshio Kanai and Yukio Kawano and Yoshihide Otani and Tetsuro Kubota and Masaki Kitajima",
year = "2002",
month = "7",
language = "English",
volume = "29",
pages = "1241--1245",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "7",

}

TY - JOUR

T1 - A novel combined chemotherapy using TS-1 and low-dose cisplatin against liver metastasis of gastric cancer

AU - Saikawa, Yoshiro

AU - Kanai, Toshio

AU - Kawano, Yukio

AU - Otani, Yoshihide

AU - Kubota, Tetsuro

AU - Kitajima, Masaki

PY - 2002/7

Y1 - 2002/7

N2 - We used a novel combination chemotherapy of TS-1 and low-dose cisplatin (CDDP) with 4 gastric cancer patients with liver metastases (one far advanced and 3 recurrent patients). TS-1 was administered at 80 mg-120 mg/body/day, twice daily for 3 weeks followed by a 2-week interval as one cycle, and CDDP was administered at 6 mg/m2/day div, for 5 days followed by a 2-day interval (1 cycle for an inpatient) or at 6 mg/m2/day div, at 5 times for 2-3 weeks (1 cycle for an outpatient). Efficacy and toxicity were evaluated after 3-6 cycles of the regimen, as long as the patients tolerated the regimen without severe side effects. This regimen resulted in 1 complete response, 2 partial responses and 1 progressive disease, showing a 75% efficacy rate. One patient experienced grade 2 nausea from this regimen, which was ameliorated by means of prolonging the interval of CDDP-administration. Thus, the regimen is useful to maintain patients' quality of life without severe adverse effects, and has a high efficacy in gastric cancer patients with liver metastases.

AB - We used a novel combination chemotherapy of TS-1 and low-dose cisplatin (CDDP) with 4 gastric cancer patients with liver metastases (one far advanced and 3 recurrent patients). TS-1 was administered at 80 mg-120 mg/body/day, twice daily for 3 weeks followed by a 2-week interval as one cycle, and CDDP was administered at 6 mg/m2/day div, for 5 days followed by a 2-day interval (1 cycle for an inpatient) or at 6 mg/m2/day div, at 5 times for 2-3 weeks (1 cycle for an outpatient). Efficacy and toxicity were evaluated after 3-6 cycles of the regimen, as long as the patients tolerated the regimen without severe side effects. This regimen resulted in 1 complete response, 2 partial responses and 1 progressive disease, showing a 75% efficacy rate. One patient experienced grade 2 nausea from this regimen, which was ameliorated by means of prolonging the interval of CDDP-administration. Thus, the regimen is useful to maintain patients' quality of life without severe adverse effects, and has a high efficacy in gastric cancer patients with liver metastases.

UR - http://www.scopus.com/inward/record.url?scp=0036635632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036635632&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 1241

EP - 1245

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 7

ER -